# A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)

> **NCT05618691** · PHASE2 · WITHDRAWN · sponsor: **Zhejiang Genfleet Therapeutics Co., Ltd.**

## Conditions studied

- Intermittent Claudication
- Peripheral Artery Disease

## Interventions

- **DRUG:** GFH312
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05618691
- **Lead sponsor:** Zhejiang Genfleet Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-12-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was terminated by sponsor for reasons of adjusted clinical development strategy.
- **Last updated:** 2023-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05618691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05618691, "A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05618691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*